AstraZeneca (AZN)
(Delayed Data from NSDQ)
$73.95 USD
+0.86 (1.18%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $74.02 +0.07 (0.09%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AZN 73.95 +0.86(1.18%)
Will AZN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AZN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AZN
Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?
AZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
Other News for AZN
Market Voices: Trump vs. Big Pharma, Swiss tariffs, tariff legality
Trump Trade: Trump signs executive order raising tariff on Canada to 35%
European pharmaceutical stocks slip after Trump pushes for lower drug prices
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'
Press Secretary says Trump sent letters today to pharmaceutical companies